COLD AND SINUS PLUS TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Disponible desde:

MARCAN PHARMACEUTICALS INC

Código ATC:

M01AE51

Designación común internacional (DCI):

IBUPROFEN, COMBINATIONS

Dosis:

2MG; 200MG; 30MG

formulario farmacéutico:

TABLET

Composición:

CHLORPHENIRAMINE MALEATE 2MG; IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Vía de administración:

ORAL

Unidades en paquete:

10/20/24/40/72/100

tipo de receta:

OTC

Área terapéutica:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0349765001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2016-09-27

Ficha técnica

1 | P a g e
PRODUCT MONOGRAPH
COLD AND SINUS PLUS
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg and
Chlorpheniramine
Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Date of Preparation:
September 27, 2016
Marcan Pharmaceuticals Inc.
77 Auriga Drive, Unit # 4
Ottawa, Ontario
K2E 7Z7
Submission Control No.: 197591
2 | P a g e
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
11
DRUG INTERACTIONS
............................................................................................................................
20
DOSAGE AND ADMINISTRATION
........................................................................................................
24
OVERDOSAGE
..........................................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
27
STORAGE AND STABILITY
....................................................................................................................
33
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
33
DOSAGE FORMS, COMPOSITIO